sur PREDILIFE (EPA:ALPRE)
PREDILIFE: 2024 Results and 2025 Outlook
PREDILIFE, a specialist in artificial intelligence for personalized medicine, has announced encouraging results for 2024. The company sold 2,200 predictive assessments, a 120% increase over the previous year, resulting in revenue of €493,000, up 55% from 2023. This momentum is accentuated by deferred income, which increased by 174% to €449,000.
The MammoRisk breast cancer screening program reached a significant milestone with the completion of the MyPeBS study, which enrolled 53,000 women. MammoRisk's potential value has been estimated at €207 million, representing significant growth potential in the European market.
PREDILIFE anticipates a doubling of sales by 2025. The company is also exploring strategic partnerships for MammoRisk, considering alliances with pharmaceutical companies, investment funds, or an IPO in either Europe or the United States.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PREDILIFE